<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985724</url>
  </required_header>
  <id_info>
    <org_study_id>CT/07.17</org_study_id>
    <nct_id>NCT01985724</nct_id>
  </id_info>
  <brief_title>Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer</brief_title>
  <official_title>A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in Women With HER-2 Negative, Axillary Lymph Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <brief_summary>
    <textblock>
      In this trial investigators propose to assess the dose dense, G-CSF supported sequential
      administration of 4 cycles of FEC followed by 4 cycles of docetaxel versus 6 cycles of
      docetaxel/cyclophosphamide as adjuvant chemotherapy in women with HER-2 negative, axillary
      lymph node positive breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anthracycline-containing regimens are recommended as adjuvant treatment for women with node
      positive breast cancer. At least five large randomized clinical trials demonstrated that the
      addition or sequential administration of a taxane (paclitaxel or docetaxel) to an
      anthracycline-based regimen resulted in superior clinical outcome for women with node
      positive or high risk node-negative early breast cancer. In two large randomized studies the
      dose dense administration with G-CSF support of anthracycline-based and paclitaxel
      combination was superior to the same regimen administered every three weeks without growth
      factors as adjuvant therapy in women with axillary node positive breast cancer. In one
      randomized trial, docetaxel was proved superior to paclitaxel in women with metastatic breast
      cancer.

      Data from at least one trial suggest that four cycles of a non-anthracycline but
      taxane-containing adjuvant regimen (docetaxel plus cyclophosphamide) provide outcomes that
      are at least as good, if not better than four cycles of doxorubicin/cyclophosphamide
      combination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>Relapses by the time of 3-years follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FEC -&gt; TXT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel/Cyclophosphamide (TC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Farmorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluoruracil</intervention_name>
    <description>ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles</description>
    <arm_group_label>A</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-colony stimulating growth factor</intervention_name>
    <description>rhG-CSF 5 Î¼g/kg/d on days 3-10 after each cycle</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Granocyte</other_name>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically-confirmed unilateral invasive ductal or lobular breast
             adenocarcinoma

          -  Within 60 days after the surgical excision of the primary tumor with tumor-free
             operation margins; at least 10 axillary lymph nodes have to be removed.

          -  Tumor involvement of at least one axillary lymph node

          -  Absence of any clinical or radiological evidence of local or metastatic disease

          -  Premenopausal or postmenopausal women aged 18-75 years old

          -  Adequate bone marrow function (absolute neutrophil count &gt;1500/mm3, platelet count
             &gt;100.000/mm3, hemoglobin &gt;10gr/mm3)

          -  Adequate liver (bilirubin &lt;1.0 times upper limit of normal and SGOT/SGPT &lt;2.5 times
             upper limit of normal) and renal function (creatinine &lt;1.5mg/dl)

          -  Adequate cardiac function (LVEF&gt;50%)

          -  Written informed consent

        Exclusion Criteria:

          -  Positive pregnancy test.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Prior or concurrent antineoplastic therapy e.g. hormonal therapy, radiation therapy,
             chemotherapy, biological agents.

          -  Previous history of other invasive malignancy other than non-melanomatous skin cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Mavrudis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Crete</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Marika Iliadis&quot; Hospital of Athens, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State General Hospital of Larissa, Dep of Medical Oncology</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2013</study_first_submitted>
  <study_first_submitted_qc>November 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early breast cancer</keyword>
  <keyword>Axillary node positive</keyword>
  <keyword>HER-2 negative</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Dose dense</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>FEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

